<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id><journal-id journal-id-type="iso-abbrev">Yonsei Med. J</journal-id><journal-id journal-id-type="publisher-id">YMJ</journal-id><journal-title-group><journal-title>Yonsei Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0513-5796</issn><issn pub-type="epub">1976-2437</issn><publisher><publisher-name>Yonsei University College of Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27189282</article-id><article-id pub-id-type="pmc">4951465</article-id><article-id pub-id-type="doi">10.3349/ymj.2016.57.4.893</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="subheading"><subject>Gastroenterology &#x00026; Hepatology</subject></subj-group></subj-group></article-categories><title-group><article-title>Cyclooxygenase-2 Inhibitor Reduces Hepatic Stiffness in Pediatric Chronic Liver Disease Patients Following Kasai Portoenterostomy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Hye Kyung</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Eun Young</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ryu</surname><given-names>Seonae</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Han</surname><given-names>Seok Joo</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pediatric Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</aff><aff id="A2"><label>2</label>Department of Pediatric Surgery, Severance Children's Hospital, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>
Corresponding author: Dr. Seok Joo Han, Department of Pediatric Surgery, Severance Children's Hospital, Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: 82-2-2228-2130, Fax: 82-2-313-8289, <email>sjhan@yuhs.ac</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>10</day><month>5</month><year>2016</year></pub-date><volume>57</volume><issue>4</issue><fpage>893</fpage><lpage>899</lpage><history><date date-type="received"><day>01</day><month>6</month><year>2015</year></date><date date-type="rev-recd"><day>24</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>25</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Copyright: Yonsei University College of Medicine 2016</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>The purpose of this study was to define the role of cyclooxygenase-2 inhibitors (COX-2i) in reducing hepatic fibrosis in pediatric patients with chronic liver disease.</p></sec><sec><title>Materials and Methods</title><p>From September 2009 to September 2010, patients over 2 years old who visited our outpatient clinic for follow-up to manage their chronic liver disease after Kasai portoenterostomy for biliary atresia, were included in this study. Volunteers were assigned to the study or control groups, according to their preference. A COX-2i was given to only the study group after obtaining consent. The degree of hepatic fibrosis (liver stiffness score, LSS) was prospectively measured using FibroScan, and liver function was examined using serum analysis before and after treatment. After 1 year, changes in LSSs and liver function were compared between the two groups.</p></sec><sec><title>Results</title><p>Twenty-five patients (18 females and 7 males) were enrolled in the study group. The control group included 44 patients (26 females and 18 males). After 1 year, the least square mean values for the LSSs were significantly decreased by 3.91&#x000b1;0.98 kPa (<italic>p</italic>=0.004) only in the study group. Serum total bilirubin did not decrease significantly in either group.</p></sec><sec><title>Conclusion</title><p>COX-2i treatment improved the LSS in patients with chronic liver disease after Kasai portoenterostomy for biliary atresia.</p></sec></abstract><kwd-group><kwd>Cyclooxygenase-2 inhibitors</kwd><kwd>liver stiffness score</kwd><kwd>hepatic fibrosis</kwd><kwd>cholestatic liver disease</kwd><kwd>biliary atresia</kwd></kwd-group><funding-group><award-group><funding-source country="KR"><institution-wrap><institution>Yonsei University College of Medicine</institution></institution-wrap></funding-source><award-id>6-2008-0296</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Most patients who undergo a Kasai portoenterostomy for biliary atresia (BA) develop chronic liver disease.<xref rid="B1" ref-type="bibr">1</xref> Cholangitis, portal hypertension, variceal bleeding, liver cirrhosis, ascites, or splenomegaly commonly occur after a Kasai portoenterostomy for BA.<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref> Hepatocellular carcinoma (HCC) that complicates biliary cirrhosis has also been reported in patients with BA.<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref></p><p>In a recent report, increased expression of cyclooxygenase-2 (COX-2) in biliary epithelial cells was found in BA patients with severe liver dysfunction at the time of the Kasai procedure.<xref rid="B6" ref-type="bibr">6</xref> Overexpression of COX-2 has been demonstrated in inflammatory, cirrhotic, or cancerous liver tissue,<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref> and many studies have tried to elucidate the role of COX-2 inhibitors (COX-2i) in hepatitis, portal hypertension, liver cirrhosis, and hepatic carcinogenesis using animal models.<xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">15</xref><xref rid="B16" ref-type="bibr">16</xref><xref rid="B17" ref-type="bibr">17</xref> Among these studies, we previously reported the effect of a selective COX-2i in reducing hepatic fibrosis in rats with ligated common bile ducts.<xref rid="B14" ref-type="bibr">14</xref></p><p>The purpose of our current study was to evaluate the effect of a COX-2i in ameliorating hepatic fibrosis or chronic inflammation in children with chronic liver disease.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patient selection</title><p>The study protocol was explained to all patients (and their parents) who were older than 2 years of age and who reported to our outpatient clinic for management of their BA after Kasai procedures. Patients, enrolled in the study and control groups, provided written informed consent, and they volunteered for the study or control group. Because the safety of the drug (meloxicam) used in the study group was not approved in children younger than 2 years of age, patients younger than 2 years were excluded from both groups.</p><p>This clinical trial was registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> (trial identification number: NCT02298218).</p></sec><sec><title>Study group</title><p>From September 2009 to September 2010, patient volunteers who were over 2 years old, who had undergone a Kasai portoenterostomy for BA, and who were postoperatively managed in our outpatient clinic were prospectively enrolled in this study. The study was approved by the Ethics Committee of Severance Hospital (approval number 4-2008-0597). Serum and urine analysis, abdominal ultrasonography, and a stool occult blood test were performed as screening tests to determine hepatic and renal function and to exclude patients with hematologic diseases, varices, or ulcers. Endoscopy of the upper gastrointestinal tract was not routinely performed as a screening test because of the invasiveness of endoscopy. If the stool occult blood test was positive, an endoscopy was performed to check for esophageal or gastric varices or ulcers. Patients with any hepatic, renal, or hematologic abnormalities or abnormal endoscopic findings were excluded. For each patient, hepatic abnormalities identified in the screening test were considered to be markedly outstanding results from the range of their previous data of serum analysis or sonographic findings.</p><p>Although patients were originally grouped into high-dose or low-dose groups using a randomized sampling method, no important differences were found. Therefore, the data were combined for all analyses. A selective COX-2i, meloxicam (Melax, Chong Kun Dang Pharm., Seoul, Korea) was prescribed to the patients once daily according to their grouping: 0.0625 mg/kg body weight in the low-dose group and 0.125 mg/kg in the high-dose group.</p><p>The degree of hepatic fibrosis was determined by the liver stiffness score (LSS) using a FibroScan (Echosens, Paris, France). The LSS was determined three times: baseline, 6 months, and 1 year after enrollment in the study group. At the 6-month time point, if the score was elevated more than 10% compared to the baseline value, the patient was excluded from the study group. If the change in the LSS at 6 months was less than or equal to 110%, the study drug was maintained for another 6 months. The LSS was determined at the 1-year time point, which corresponded to the time of study completion. Liver function was checked by serum analysis before and after receiving the COX-2i.</p><p>Patients visited the outpatient clinic every 3 months to check for any adverse effects of the drug. Furthermore, serum analysis, including a blood cell count, analysis of hepatic and renal function, urinalysis, abdominal ultrasonography, and a stool occult blood test were performed every 3 months. The trough level of the drug in the serum was checked to maintain the concentration of the drug in the proper range. If any suspicious adverse effect of the drug was noted, the patient was excluded from the study.</p></sec><sec><title>Control group</title><p>The LSS has been determined in patients with BA every year at our outpatient clinic since the introduction of the FibroScan in 2007. The control group included patients who were followed at our outpatient clinic after successful Kasai portoenterostomy for BA and who simultaneously had their LSS and serum total bilirubin measured two or more times during the post-operative follow-up period. LSS was measured two times every 6 months after enrollment in the control group. We excluded the LSS from our analysis of patients in the control group when the LSS was measured with a success rate lower than 60%, when patients had hyperbilirubinemia (elevation of serum total bilirubin &#x02265;1.0 mg/dL compared to the baseline), after a repeat-Kasai procedure, or after liver transplantation. Except for medication with the COX-2i in the study group, all management procedures after the Kasai portoenterostomy were the same in both groups, including administration of ursodeoxycholic acid, antibiotics to prevent cholangitis, and the use of transient steroid therapy.</p></sec><sec><title>Measurement of LSS</title><p>LSS was measured in both groups as described previously.<xref rid="B18" ref-type="bibr">18</xref> In brief, the patient was placed in a supine position with maximal abduction of the right arm. Ten successful measurements of LSS were obtained with an ultrasound transduced probe on the right lobe of the liver through the intercostal spaces. The median value of the 10 measurements of LSS was calculated automatically by software in FibroScan and expressed as LSS in kilopascals (kPa).</p></sec><sec><title>Data analysis</title><p>The LSS and serum total bilirubin values in both groups were collected retrospectively for a period of 2 years before enrollment in the study, and they were compared with those values after study enrollment. The median LSS value and the average of the serum total bilirubin for each patient were used as the baseline values.</p><p>Statistical analyses were performed using SPSS version 18.0 software (SPSS Inc., Chicago, IL, USA) and SAS version 9.2 software (SAS Institute Inc., Cary, NC, USA). Categorical parameters were analyzed with Pearson's chi-squared test. Continuous parametric data were analyzed with independent t test. Paired non-parametric data were analyzed with Wilcoxon signed-rank test. The effects of the study drug on LSS, serum bilirubin, and liver enzymes were compared between the two groups using a linear mixed model. <italic>P</italic> values for multiple comparisons were adjusted with post-hoc analysis using Bonferroni's correction. A <italic>p</italic> value less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The clinical characteristics of both groups are presented in <xref ref-type="table" rid="T1">Table 1</xref>. Twenty-five patients were enrolled in the study group (18 females and 7 males) with an average age at enrollment of 6.1&#x000b1;3.0 years. The control group included 44 patients (26 females and 18 males) with an average age at enrollment of 5.5&#x000b1;3.2 years. The mean age at the time of Kasai portoenterostomy for BA was not significantly different between the two groups (66.3&#x000b1;36.6 days in the study group vs. 58.0&#x000b1;25.3 days in the control group; <italic>p</italic>=0.279). Thirteen patients (10 females and 3 males) were assigned randomly to the low-dose group prescribed 0.0625 mg/kg body weight COX-2i, and 12 patients (8 females and 4 males) were assigned to the high-dose group prescribed 0.125 mg/kg COX-2i.</p><p>The average value for serum total bilirubin before study enrollment was not different between the two groups (1.4&#x000b1;0.7 mg/dL in the study group vs. 0.9&#x000b1;1.5 mg/dL in the control group; <italic>p</italic>=0.175). However, the mean LSS before study enrollment was higher in the study group than in the control group (20.5&#x000b1;9.7 kPa in the study group vs. 11.8&#x000b1;8.9 kPa in the control group; <italic>p</italic>&#x0003c;0.001) (<xref ref-type="table" rid="T1">Table 1</xref>). The success rate of obtaining LSS before study enrollment was more than 90% in both groups (96.7&#x000b1;9.0% in the study group vs. 93.2&#x000b1;10.7% in the control group; <italic>p</italic>=0.153). During the study, no LSS data were excluded because all measured success rates of LSS were higher than 80% in both groups.</p><p>The least square means (LSM) of the LSS in the study group were significantly decreased by 3.91&#x000b1;0.98 kPa at the 1-year time point. In contrast, the LSS in the control group did not change significantly during the study period with a difference of -0.29&#x000b1;0.70 kPa (<italic>p</italic>=0.004) (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). Serum total bilirubin levels did not change significantly in either group during the study period (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). Differences of the LSM of serum total bilirubin during the 1-year study period were -0.34&#x000b1;0.17 mg/dL in the study group and 0.02&#x000b1;0.08 mg/dL in the control group (<italic>p</italic>=0.071) (<xref ref-type="table" rid="T2">Table 2</xref>). The liver enzymes [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] in either group did not change significantly during the study period (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F1">Fig. 1C and D</xref>).</p><p>During the study period, the mean serum drug level in the study group was 0.27&#x000b1;0.17 &#x000b5;g/mL. Considering the possible side effects of COX-2i, we performed serum analysis including a blood cell count, hepatic and renal function tests, urinalysis, abdominal ultrasonography, and stool occult blood test every 3 months. LSS was measured 6 months after the start of medication. If the LSS was elevated by more than 10% at the 6-month time point compared to baseline, or if an abnormal finding showed up in the follow-up tests every 3 months, we excluded the patient from the study group to prevent the possible occurrence of hepatic toxicity or other adverse effect of the drug. Three patients in the study group (two in the high-dose group and one in the low-dose group) were excluded at the 6-month time point, because their LSS were elevated by more than 10% compared to baseline. However, the median values of their LSSs were not significantly different with 12.60 (7.75&#x02013;27.90) kPa at baseline LSS and 13.50 (9.50&#x02013;45.00) kPa at the 6-month time point (<italic>p</italic>=0.109). Moreover, serum total bilirubin and liver enzymes were unchanged at the 6-month time point (<italic>p</italic>=0.102 for serum total bilirubin, <italic>p</italic>=0.102 for AST, and <italic>p</italic>=0.109 for ALT). Their elevated LSSs and the other data obtained at the 6-month time point were included in the data analysis as the study group without the data at the 12-month time point. Moreover, no adverse effects due to COX-2i were noted in this study. The results of the serum analysis and the urinalysis indicated that hematologic, hepatic, and renal function values were not affected by the use of COX-2i during the study. The occult blood test result was negative for every stool test. When they were asked during follow-up visits, none of the patients complained of nausea, vomiting, diarrhea, bloody stool, indigestion, abdominal pain, heartburn, chest discomfort or tightness, mood change, anxiety, change in appetite, skin rash, irritability, abnormal sensation, changes in vision, confusion, or loss of consciousness.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Despite the overall success of the Kasai procedure for BA,<xref rid="B19" ref-type="bibr">19</xref><xref rid="B20" ref-type="bibr">20</xref> many children with BA experience liver damage after the procedure.<xref rid="B2" ref-type="bibr">2</xref> This liver damage, which includes fibrosis and cholangitis, can lead to chronic liver disease with portal hypertension, cirrhosis, or even HCC and the need for a liver transplant.<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref><xref rid="B21" ref-type="bibr">21</xref><xref rid="B22" ref-type="bibr">22</xref> Although approximately 80&#x02013;90% of patients who undergo the Kasai procedure or even liver transplantation survive to adolescence and beyond,<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref><xref rid="B20" ref-type="bibr">20</xref> these patients experience substantial morbidity. Liver fibrosis and cirrhosis begin early in infants with BA.<xref rid="B2" ref-type="bibr">2</xref> Corticosteroids may help limit inflammatory damage and increase bile flow, but their efficacy remains unclear.<xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref> Therefore, additional pharmacological treatments are required to improve liver function in these patients.</p><p>Overexpression of COX-2 in the liver has been observed in patients with chronic hepatitis, cirrhosis, and HCC,<xref rid="B7" ref-type="bibr">7</xref><xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref><xref rid="B15" ref-type="bibr">15</xref><xref rid="B16" ref-type="bibr">16</xref> and COX-2 may mediate or worsen these conditions.<xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref><xref rid="B9" ref-type="bibr">9</xref><xref rid="B15" ref-type="bibr">15</xref> Liver fibrosis is caused by cholestasis and collagen accumulation, and COX-2 is upregulated with these conditions.<xref rid="B13" ref-type="bibr">13</xref> COX-2 expression also correlates with the stage of fibrosis.<xref rid="B9" ref-type="bibr">9</xref> Mohammed, et al.<xref rid="B7" ref-type="bibr">7</xref> analyzed COX-2 expression in cirrhotic livers after hepatitis B and C infection and found that COX-2 was absent in normal livers but high in cirrhotic livers. Jeong, et al.<xref rid="B23" ref-type="bibr">23</xref> examined COX-2 protein expression in 43 patients with chronic hepatitis and 24 patients with cirrhosis using immunohistochemistry and found that COX-2 expression was higher in patients with cirrhosis and advanced fibrosis. Honsawek, et al.<xref rid="B6" ref-type="bibr">6</xref> reported that COX-2 expression was increased in biliary epithelial cells at the time of Kasai portoenterostomy in patients with BA and was associated with an adverse postoperative outcome.</p><p>In addition, COX-2 may be involved in the development of HCC resulting from chronic liver disease. In patients with HCC and hepatitis C virus-related cirrhosis, overexpression of COX-2 may accelerate the development of HCC, and higher COX-2 expression is a significant risk factor for recurrence of HCC in the residual liver.<xref rid="B8" ref-type="bibr">8</xref> He, et al.<xref rid="B24" ref-type="bibr">24</xref> evaluated COX-2 expression in the liver of patients with HCC and showed that the recurrence-free survival rates in the COX-2-positive group were significantly lower than those in the COX-2-negative group. These authors speculated that overexpression of COX-2 in the noncancerous liver may predict cancer recurrence in patients with hepatitis B virus-related cirrhosis.<xref rid="B24" ref-type="bibr">24</xref> Thus, blocking COX-2 activity may improve liver function and prevent further damage in different groups of patients, including those with BA.</p><p>The effect of inhibiting COX-2 has been explored in several animal models of liver disease. In rats treated with carbon tetrachloride to induce liver cirrhosis, the COX-2i rofecoxib reduces portal pressure, collagen accumulation, and fibrogenesis.<xref rid="B11" ref-type="bibr">11</xref> Using a similar rat model, Ch&#x000e1;vez, et al.<xref rid="B12" ref-type="bibr">12</xref> showed that the COX-2i celecoxib prevents and reduces cholestatic damage and collagen deposition, demonstrating the antifibrogenic and fibrolytic effects of this COX-2i. Similarly, carbon tetrachloride-treated mice given the COX-2i SC-236 show reduced liver fibrosis.<xref rid="B13" ref-type="bibr">13</xref> In an animal study,<xref rid="B14" ref-type="bibr">14</xref> we performed bile duct ligation in rats to induce cholestasis, which triggers fibrogenesis in the liver, and subsequently treated the rats with the COX-2i meloxicam, and found that meloxicam reduces fibrosis and collagen accumulation, with corresponding histological improvement of the liver by attenuating the expression of &#x003b1;-smooth muscle actin, transforming growth factor-&#x003b2;1, COX-2, and matrix metalloproteinase-9. The preventive effect of meloxicam was also reported in the rat hepatic ischemia/reperfusion injury model.<xref rid="B15" ref-type="bibr">15</xref> Yamamoto, et al.<xref rid="B10" ref-type="bibr">10</xref> showed that the COX-2i JTE-522 prevents liver fibrosis in rats that were fed a choline- and L-amino acid-deficient diet or thioacetamide to induce fibrosis. Thus, inhibiting COX-2 seems to prevent many different types of liver damage from a variety of causes in animals. In a recent report, Edfawy, et al.<xref rid="B16" ref-type="bibr">16</xref> suggested that the hepatoprotective effect of COX-2i could be ascribed to its antioxidant potential, free radical scavenging properties, anti-inflammatory effect, and ability to abrogate apoptosis via suppression of active caspase 3. In another study, selective COX-2i played a role in decreasing portal hypertension via its dual inhibitory effects on intrahepatic fibrosis and angiogenesis.<xref rid="B17" ref-type="bibr">17</xref> The antifibrotic effects of COX-2i have been shown in models of fibrosis in other organs including the heart,<xref rid="B25" ref-type="bibr">25</xref> lung,<xref rid="B26" ref-type="bibr">26</xref> kidney,<xref rid="B27" ref-type="bibr">27</xref><xref rid="B28" ref-type="bibr">28</xref> and peritoneum.<xref rid="B29" ref-type="bibr">29</xref> To our knowledge, however, no study of human subjects has found that COX-2i can prevent liver damage; the present study is the first to find an ameliorating effect of COX-2i in humans with chronic liver disease.</p><p>In this study, the study group initially had a higher mean LSS, which indicates more advanced liver disease compared to the control group. This difference in patient groups might have been caused by the voluntary grouping of the patients. Sicker patients may want another option to manage their chronic liver disease. However, after medication with COX-2i, most patients in the study group had improved LSS. Although LSS decreased over time in both groups, it was significantly decreased only in the study group. Thus, treatment with COX-2i can reduce the LSS in patients with chronic liver disease after Kasai portoenterostomy for BA.</p><p>Meloxicam is a non-steroidal anti-inflammatory drug used to treat pain and inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. The usual pediatric dosage for juvenile rheumatoid arthritis is 0.125 mg/kg/day, which was the dosage in our high-dose group. The maximal dose for juvenile rheumatoid arthritis is 7.5 mg/day. No dosage adjustment is needed in patients with mild to moderate hepatic or renal insufficiency.<xref rid="B30" ref-type="bibr">30</xref> Reduction of the LSS was achieved in our study group using the universal dosage for juvenile rheumatoid arthritis or even 50% of that dose. No adverse reaction related to the COX-2i was found after the 1-year study period. The LSS in the study group was significantly decreased only after administration for 1 year (not for 6 months) compared to the control group. Therefore, we cautiously suggest that long-term treatment for 1 year may be necessary to reduce the LSS without drug side effects in pediatric patients with chronic liver disease.</p><p>At the midpoint of the study, we excluded three patients from the study group because of their elevated LSS to prevent possible hepatic adverse effects of the study drug. Doing so may have provided a potential bias in analyzing the result by comparing the study and control groups. However, two of the three excluded patients had a lower LSS than the mean LSS of the study group. Therefore, the bias from the exclusion of these three patients may not be significant.</p><p>The LSS is known to be affected by liver fibrosis, cholestasis (which is correlated with serum bilirubin), and necroinflammation of the liver (which is represented by elevated liver enzymes, AST or ALT).<xref rid="B31" ref-type="bibr">31</xref><xref rid="B32" ref-type="bibr">32</xref><xref rid="B33" ref-type="bibr">33</xref><xref rid="B34" ref-type="bibr">34</xref><xref rid="B35" ref-type="bibr">35</xref><xref rid="B36" ref-type="bibr">36</xref> In our study, treatment with a COX-2i improved the LSS in cholestatic patients with BA who had undergone a Kasai portoenterostomy; however, cholestasis, as measured by total bilirubin, and necroinflammatory activity of the liver, as measured by ALT or AST, were not changed. Therefore, the decrease in LSS indicates that the COX-2i ameliorated liver fibrosis.</p><p>In conclusion, COX-2i has a beneficial effect on hepatic fibrosis in children with chronic liver disease after Kasai portoenterostomy for BA. Accordingly, COX-2i may have a preventive effect against hepatic fibrosis in our study group, considering the progression of hepatic fibrosis in the patients with BA even after Kasai portoenterostomy. COX2i may be a promising new treatment for preventing or reducing hepatic fibrosis after Kasai portoenterostomy for BA. Long-term treatment with a universal dose of a COX-2i was safe and did not lead to complications in these young patients with chronic liver disease. Further studies are needed to determine the optimal duration and dosage of the COX-2i in children with chronic liver disease and the optimal time to begin therapy with a COX-2i after the initial Kasai procedure.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>This research was supported by a grant from Yonsei University College of Medicine (grant number 6-2008-0296).</p></ack><fn-group><fn fn-type="conflict"><p>The authors have no financial conflicts of interest.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadzi&#x00107;</surname><given-names>N</given-names></name><name><surname>Davenport</surname><given-names>M</given-names></name><name><surname>Tizzard</surname><given-names>S</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>ER</given-names></name><name><surname>Mieli-Vergani</surname><given-names>G</given-names></name></person-group><article-title>Long-term survival following Kasai portoenterostomy: is chronic liver disease inevitable?</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2003</year><volume>37</volume><fpage>430</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">14508212</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartley</surname><given-names>JL</given-names></name><name><surname>Davenport</surname><given-names>M</given-names></name><name><surname>Kelly</surname><given-names>DA</given-names></name></person-group><article-title>Biliary atresia</article-title><source>Lancet</source><year>2009</year><volume>374</volume><fpage>1704</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">19914515</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>M</given-names></name></person-group><article-title>Biliary atresia: clinical aspects</article-title><source>Semin Pediatr Surg</source><year>2012</year><volume>21</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">22800970</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Had&#x0017e;i&#x00107;</surname><given-names>N</given-names></name><name><surname>Quaglia</surname><given-names>A</given-names></name><name><surname>Portmann</surname><given-names>B</given-names></name><name><surname>Paramalingam</surname><given-names>S</given-names></name><name><surname>Heaton</surname><given-names>ND</given-names></name><name><surname>Rela</surname><given-names>M</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma in biliary atresia: King's College Hospital experience</article-title><source>J Pediatr</source><year>2011</year><volume>159</volume><fpage>617</fpage><lpage>622.e1</lpage><pub-id pub-id-type="pmid">21489554</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hol</surname><given-names>L</given-names></name><name><surname>van den Bos</surname><given-names>IC</given-names></name><name><surname>Hussain</surname><given-names>SM</given-names></name><name><surname>Zondervan</surname><given-names>PE</given-names></name><name><surname>de Man</surname><given-names>RA</given-names></name></person-group><article-title>Hepatocellular carcinoma complicating biliary atresia after Kasai portoenterostomy</article-title><source>Eur J Gastroenterol Hepatol</source><year>2008</year><volume>20</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">18301305</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honsawek</surname><given-names>S</given-names></name><name><surname>Klaikeaw</surname><given-names>N</given-names></name><name><surname>Vejchapipat</surname><given-names>P</given-names></name><name><surname>Chongsrisawat</surname><given-names>V</given-names></name><name><surname>Ruangvejvorachai</surname><given-names>P</given-names></name><name><surname>Poovorawan</surname><given-names>Y</given-names></name></person-group><article-title>Cyclooxygenase-2 overexpression is associated with clinical outcome in biliary atresia</article-title><source>Eur J Pediatr Surg</source><year>2010</year><volume>20</volume><fpage>164</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">20084600</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>NA</given-names></name><name><surname>Abd El-Aleem</surname><given-names>SA</given-names></name><name><surname>El-Hafiz</surname><given-names>HA</given-names></name><name><surname>McMahon</surname><given-names>RF</given-names></name></person-group><article-title>Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis</article-title><source>J Clin Pathol</source><year>2004</year><volume>57</volume><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">15047734</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morinaga</surname><given-names>S</given-names></name><name><surname>Tarao</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Rino</surname><given-names>Y</given-names></name><name><surname>Miyakawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma</article-title><source>J Gastroenterol Hepatol</source><year>2007</year><volume>22</volume><fpage>1249</fpage><lpage>1255</lpage><pub-id pub-id-type="pmid">17688665</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pazirandeh</surname><given-names>S</given-names></name><name><surname>Khettry</surname><given-names>U</given-names></name><name><surname>Gordon</surname><given-names>FD</given-names></name><name><surname>Resnick</surname><given-names>RH</given-names></name><name><surname>Murray</surname><given-names>JE</given-names></name><name><surname>Sheth</surname><given-names>SG</given-names></name></person-group><article-title>Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States</article-title><source>Dig Dis Sci</source><year>2007</year><volume>52</volume><fpage>220</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">17160481</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Nakamori</surname><given-names>S</given-names></name><name><surname>Nagano</surname><given-names>H</given-names></name><name><surname>Wakasa</surname><given-names>K</given-names></name><name><surname>Sugita</surname><given-names>Y</given-names></name><etal/></person-group><article-title>JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><fpage>556</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">12891558</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>CT</given-names></name><name><surname>Guo</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>JY</given-names></name></person-group><article-title>Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury</article-title><source>J Gastroenterol Hepatol</source><year>2007</year><volume>22</volume><fpage>877</fpage><lpage>884</lpage><pub-id pub-id-type="pmid">17565644</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ch&#x000e1;vez</surname><given-names>E</given-names></name><name><surname>Segovia</surname><given-names>J</given-names></name><name><surname>Shibayama</surname><given-names>M</given-names></name><name><surname>Tsutsumi</surname><given-names>V</given-names></name><name><surname>Vergara</surname><given-names>P</given-names></name><name><surname>Castro-S&#x000e1;nchez</surname><given-names>L</given-names></name><etal/></person-group><article-title>Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat</article-title><source>Liver Int</source><year>2010</year><volume>30</volume><fpage>969</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">20524983</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horrillo</surname><given-names>R</given-names></name><name><surname>Planagum&#x000e0;</surname><given-names>A</given-names></name><name><surname>Gonz&#x000e1;lez-P&#x000e9;riz</surname><given-names>A</given-names></name><name><surname>Ferr&#x000e9;</surname><given-names>N</given-names></name><name><surname>Titos</surname><given-names>E</given-names></name><name><surname>Miquel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor</article-title><source>J Pharmacol Exp Ther</source><year>2007</year><volume>323</volume><fpage>778</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">17766677</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Park</surname><given-names>KC</given-names></name><name><surname>Kim</surname><given-names>HG</given-names></name><name><surname>Han</surname><given-names>SJ</given-names></name></person-group><article-title>Effect of selective cyclooxygenase-2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts</article-title><source>Hepatol Res</source><year>2008</year><volume>38</volume><fpage>800</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">18462380</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tolba</surname><given-names>RH</given-names></name><name><surname>Fet</surname><given-names>N</given-names></name><name><surname>Yonezawa</surname><given-names>K</given-names></name><name><surname>Taura</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>A</given-names></name><name><surname>Hata</surname><given-names>K</given-names></name><etal/></person-group><article-title>Role of preferential cyclooxygenase-2 inhibition by meloxicam in ischemia/reperfusion injury of the rat liver</article-title><source>Eur Surg Res</source><year>2014</year><volume>53</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">24854565</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edfawy</surname><given-names>M</given-names></name><name><surname>Hassan</surname><given-names>MH</given-names></name><name><surname>Mansour</surname><given-names>A</given-names></name><name><surname>Hamed</surname><given-names>AA</given-names></name><name><surname>Amin</surname><given-names>HA</given-names></name></person-group><article-title>Meloxicam modulates oxidative stress status, inhibits prostaglandin E2, and abrogates apoptosis in carbon tetrachloride-induced rat hepatic injury</article-title><source>Int J Toxicol</source><year>2012</year><volume>31</volume><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">22556387</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JH</given-names></name><name><surname>Wen</surname><given-names>SL</given-names></name><name><surname>Yang</surname><given-names>WJ</given-names></name><name><surname>Lu</surname><given-names>YY</given-names></name><name><surname>Tong</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>ZY</given-names></name><etal/></person-group><article-title>Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e69309</fpage><pub-id pub-id-type="pmid">23922700</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>HK</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Koh</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>SM</given-names></name><name><surname>Chung</surname><given-names>KS</given-names></name><name><surname>Oh</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Hepatic fibrosis scan for liver stiffness score measurement: a useful preendoscopic screening test for the detection of varices in postoperative patients with biliary atresia</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2009</year><volume>49</volume><fpage>323</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">19633573</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinkai</surname><given-names>M</given-names></name><name><surname>Ohhama</surname><given-names>Y</given-names></name><name><surname>Take</surname><given-names>H</given-names></name><name><surname>Kitagawa</surname><given-names>N</given-names></name><name><surname>Kudo</surname><given-names>H</given-names></name><name><surname>Mochizuki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Long-term outcome of children with biliary atresia who were not transplanted after the Kasai operation: &#x0003e;20-year experience at a children's hospital</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2009</year><volume>48</volume><fpage>443</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">19330933</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chardot</surname><given-names>C</given-names></name><name><surname>Buet</surname><given-names>C</given-names></name><name><surname>Serinet</surname><given-names>MO</given-names></name><name><surname>Golmard</surname><given-names>JL</given-names></name><name><surname>Lachaux</surname><given-names>A</given-names></name><name><surname>Roquelaure</surname><given-names>B</given-names></name><etal/></person-group><article-title>Improving outcomes of biliary atresia: French national series 1986-2009</article-title><source>J Hepatol</source><year>2013</year><volume>58</volume><fpage>1209</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">23402746</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumagi</surname><given-names>T</given-names></name><name><surname>Drenth</surname><given-names>JP</given-names></name><name><surname>Guttman</surname><given-names>O</given-names></name><name><surname>Ng</surname><given-names>V</given-names></name><name><surname>Lilly</surname><given-names>L</given-names></name><name><surname>Therapondos</surname><given-names>G</given-names></name><etal/></person-group><article-title>Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review</article-title><source>Liver Int</source><year>2012</year><volume>32</volume><fpage>510</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">22098694</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>VL</given-names></name><name><surname>Haber</surname><given-names>BH</given-names></name><name><surname>Magee</surname><given-names>JC</given-names></name><name><surname>Miethke</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>KF</given-names></name><name><surname>Michail</surname><given-names>S</given-names></name><etal/></person-group><article-title>Medical status of 219 children with biliary atresia surviving long-term with their native livers: results from a North American multicenter consortium</article-title><source>J Pediatr</source><year>2014</year><volume>165</volume><fpage>539</fpage><lpage>546.e2</lpage><pub-id pub-id-type="pmid">25015575</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>SW</given-names></name><name><surname>Jang</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Cheon</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis</article-title><source>Korean J Intern Med</source><year>2010</year><volume>25</volume><fpage>364</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">21179273</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>YF</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Ji</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis</article-title><source>Can J Gastroenterol</source><year>2010</year><volume>24</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">20652159</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>BH</given-names></name><name><surname>Bertucci</surname><given-names>MC</given-names></name><name><surname>Ma</surname><given-names>JY</given-names></name><name><surname>Adrahtas</surname><given-names>A</given-names></name><name><surname>Cheung</surname><given-names>RY</given-names></name><name><surname>Krum</surname><given-names>H</given-names></name></person-group><article-title>Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone</article-title><source>Clin Exp Pharmacol Physiol</source><year>2010</year><volume>37</volume><fpage>912</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">20497423</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arafa</surname><given-names>HM</given-names></name><name><surname>Abdel-Wahab</surname><given-names>MH</given-names></name><name><surname>El-Shafeey</surname><given-names>MF</given-names></name><name><surname>Badary</surname><given-names>OA</given-names></name><name><surname>Hamada</surname><given-names>FM</given-names></name></person-group><article-title>Anti-fibrotic effect of meloxicam in a murine lung fibrosis model</article-title><source>Eur J Pharmacol</source><year>2007</year><volume>564</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">17462625</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>P</given-names></name></person-group><article-title>Do COX-2 inhibitors reduce renal fibrosis?</article-title><source>J Hypertens</source><year>2004</year><volume>22</volume><fpage>43</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15106792</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucuk</surname><given-names>HF</given-names></name><name><surname>Bingul</surname><given-names>SM</given-names></name><name><surname>Kurt</surname><given-names>N</given-names></name><name><surname>Kaptanoglu</surname><given-names>L</given-names></name><name><surname>Akyol</surname><given-names>H</given-names></name><name><surname>Torlak</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Effect of a selective cyclooxygenase-2 inhibitor on renal scarring</article-title><source>Eur Surg Res</source><year>2006</year><volume>38</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">16912484</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabbrini</surname><given-names>P</given-names></name><name><surname>Schilte</surname><given-names>MN</given-names></name><name><surname>Zareie</surname><given-names>M</given-names></name><name><surname>ter Wee</surname><given-names>PM</given-names></name><name><surname>Keuning</surname><given-names>ED</given-names></name><name><surname>Beelen</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Celecoxib treatment reduces peritoneal fibrosis and angiogenesis and prevents ultrafiltration failure in experimental peritoneal dialysis</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>3669</fpage><lpage>3676</lpage><pub-id pub-id-type="pmid">19666665</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="webpage"><collab>Drugs.com</collab><source>Meloxicam</source><date-in-citation content-type="access-date">accessed on 2008 November 16</date-in-citation><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.drugs.com/meloxicam.html">http://www.drugs.com/meloxicam.html</ext-link></comment></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millonig</surname><given-names>G</given-names></name><name><surname>Reimann</surname><given-names>FM</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Fonouni</surname><given-names>H</given-names></name><name><surname>Mehrabi</surname><given-names>A</given-names></name><name><surname>B&#x000fc;chler</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><fpage>1718</fpage><lpage>1723</lpage><pub-id pub-id-type="pmid">18836992</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraquelli</surname><given-names>M</given-names></name><name><surname>Rigamonti</surname><given-names>C</given-names></name><name><surname>Casazza</surname><given-names>G</given-names></name><name><surname>Conte</surname><given-names>D</given-names></name><name><surname>Donato</surname><given-names>MF</given-names></name><name><surname>Ronchi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease</article-title><source>Gut</source><year>2007</year><volume>56</volume><fpage>968</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">17255218</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coco</surname><given-names>B</given-names></name><name><surname>Oliveri</surname><given-names>F</given-names></name><name><surname>Maina</surname><given-names>AM</given-names></name><name><surname>Ciccorossi</surname><given-names>P</given-names></name><name><surname>Sacco</surname><given-names>R</given-names></name><name><surname>Colombatto</surname><given-names>P</given-names></name><etal/></person-group><article-title>Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases</article-title><source>J Viral Hepat</source><year>2007</year><volume>14</volume><fpage>360</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">17439526</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagir</surname><given-names>A</given-names></name><name><surname>Erhardt</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>H&#x000e4;ussinger</surname><given-names>D</given-names></name></person-group><article-title>Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><fpage>592</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">18098325</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arena</surname><given-names>U</given-names></name><name><surname>Vizzutti</surname><given-names>F</given-names></name><name><surname>Corti</surname><given-names>G</given-names></name><name><surname>Ambu</surname><given-names>S</given-names></name><name><surname>Stasi</surname><given-names>C</given-names></name><name><surname>Bresci</surname><given-names>S</given-names></name><etal/></person-group><article-title>Acute viral hepatitis increases liver stiffness values measured by transient elastography</article-title><source>Hepatology</source><year>2008</year><volume>47</volume><fpage>380</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">18095306</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Kawabe</surname><given-names>N</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name></person-group><article-title>Transient elastography: applications and limitations</article-title><source>Hepatol Res</source><year>2008</year><volume>38</volume><fpage>1063</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">18624715</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Changes in liver parameters according to the study time points for the study and control groups. (A) Median values of the liver stiffness score (LSS). (B) Mean values of serum total bilirubin (TB). (C) Mean values of aspartate aminotransferase (AST). (D) Mean values of alanine aminotransferase (ALT). The significant difference (<italic>p</italic>&#x0003c;0.05) is indicated with an asterisk.</title></caption><graphic xlink:href="ymj-57-893-g001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Clinical Characteristics of the Study Population</title></caption><alternatives><graphic xlink:href="ymj-57-893-i001"/><table frame="hsides" rules="rows"><col width="50%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="10%" span="1"/><thead><tr><th valign="top" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Study group (n=25)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Control group (n=44)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"><italic>p</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex, n (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="right" rowspan="1" colspan="1">0.284</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;Male</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">7 (28.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">18 (40.9)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="top" align="center" rowspan="1" colspan="1">18 (72.0)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (59.1)</td><td valign="top" align="right" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Mean age at study enrollment, yrs</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">6.1&#x000b1;3.0</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">5.5&#x000b1;3.2</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.479</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean age at Kasai portoenterostomy for BA, days</td><td valign="top" align="center" rowspan="1" colspan="1">66.3&#x000b1;36.6</td><td valign="top" align="center" rowspan="1" colspan="1">58.0&#x000b1;25.3</td><td valign="top" align="right" rowspan="1" colspan="1">0.279</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Mean LSS (kPa) before study enrollment</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">20.5&#x000b1;9.7</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">11.8&#x000b1;8.9</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean TB (mg/dL) before study enrollment</td><td valign="top" align="center" rowspan="1" colspan="1">1.4&#x000b1;0.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.9&#x000b1;1.5</td><td valign="top" align="right" rowspan="1" colspan="1">0.175</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Mean AST (IU/L) before study enrollment</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">82.6&#x000b1;47.2</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">57.6&#x000b1;44.3</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.063</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mean ALT (IU/L) before study enrollment</td><td valign="top" align="center" rowspan="1" colspan="1">67.0&#x000b1;46.4</td><td valign="top" align="center" rowspan="1" colspan="1">54.3&#x000b1;53.7</td><td valign="top" align="right" rowspan="1" colspan="1">0.380</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>BA, biliary atresia; LSS, liver stiffness score; kPa, kilopascals; TB, serum total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>The Differences of Least Square Mean Values of the LSS, TB, and Liver Enzyme Values at Baseline, 6-Month, and 1-Year Time Points</title></caption><alternatives><graphic xlink:href="ymj-57-893-i002"/><table frame="hsides" rules="rows"><col width="45%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="15%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Study group (n=25)</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Control group (n=44)</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"><italic>p</italic> value</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">LSS (kPa)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;6-month time point</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-2.36&#x000b1;1.22</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-0.39&#x000b1;0.92</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.203</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;1-yr time point</td><td valign="top" align="center" rowspan="1" colspan="1">-3.91&#x000b1;0.98</td><td valign="top" align="center" rowspan="1" colspan="1">-0.29&#x000b1;0.70</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">TB (mg/dL)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6-month time point</td><td valign="top" align="center" rowspan="1" colspan="1">-0.18&#x000b1;0.15</td><td valign="top" align="center" rowspan="1" colspan="1">-0.13&#x000b1;0.06</td><td valign="top" align="center" rowspan="1" colspan="1">0.756</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;1-yr time point</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-0.34&#x000b1;0.17</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.02&#x000b1;0.08</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.071</td></tr><tr><td valign="top" rowspan="1" colspan="1">AST (IU/L)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;6-month time point</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-0.42&#x000b1;8.86</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-15.44&#x000b1;6.70</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.181</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;1-yr time point</td><td valign="top" align="center" rowspan="1" colspan="1">-13.41&#x000b1;8.40</td><td valign="top" align="center" rowspan="1" colspan="1">-21.37&#x000b1;6.24</td><td valign="top" align="center" rowspan="1" colspan="1">0.450</td></tr><tr><td valign="top" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">ALT (IU/L)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;6-month time point</td><td valign="top" align="center" rowspan="1" colspan="1">-2.33&#x000b1;11.38</td><td valign="top" align="center" rowspan="1" colspan="1">-15.42&#x000b1;8.58</td><td valign="top" align="center" rowspan="1" colspan="1">0.362</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;1-yr time point</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-10.10&#x000b1;10.18</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-22.75&#x000b1;7.46</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.320</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>LSS, liver stiffness scores; TB, serum total bilirubin; kPa, kilopascals; AST, aspartate aminotransferase; ALT, alanine aminotransferase.</p></fn></table-wrap-foot></table-wrap></floats-group></article>